Swedish biopharmaceutical company Sobi (STO:SOBI) on Thursday reported positive topline results from its pivotal Phase 3 REDUCE 2 study of pozdeutinurad (AR882) in adults with gout including those with uncontrolled gout (also referred to as progressive gout) and inadequately controlled by existing therapies.

Pozdeutinurad is an investigational next-generation once-daily oral selective URAT1 inhibitor.

In the study, both doses of pozdeutinurad met the primary efficacy endpoint, defined as the proportion of patients achieving a serum uric acid (sUA) level